Has anyone dealt with glp-1 receptor agonists and thyroid c-cell concerns?

Taking the question as asked, rather than the general version of it. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

CarlaRPh_TPA said:

The mechanism is more central than most summaries suggest.

Agreed, and the adaptation point cuts both ways: tachyphylaxis to gastric emptying is why tolerability improves, and it is also why people who were relying on physical fullness feel the effect fade while the appetite effect is still working.

wanda_boise said:

My prescriber wanted a baseline TSH and did not want a calcitonin, and I would like to understand the reasoning rather than just accepting it.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

Adding the clinical framing, because it changes how the question reads.

Thyroid cancer screening labs for thyroid monitoring — addressing the boxed warning concern with actual data:

Calcitonin level: 3.0 pg/mL (normal <10). Checked at baseline, month 6, and month 12. Rock stable, no upward trend.

Thyroid ultrasound: normal, no nodules at month 12.

The MTC risk from rodent studies has not been confirmed in human post-marketing data across millions of patient-years. The boxed warning is a regulatory precaution based on animal data. While monitoring is prudent, the clinical risk appears to be negligible.